Skip to main content
SpringerLink
Log in

Idarubicin (4-demethoxydaunorubicin)

A preliminary overview of preclinical and clinical studies

  • Reviews
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

4-Demethoxydaunorubicin (4-DMDR, IMI 30, Idarubicin, NSC 256439) is a new analog of daunorubicin (DNR) with antileukemic activity in experimental systems that is superior to that of daunorubicin (DNR) or doxorubicin (DX). The drug is more potent than DNR and DX and is active by both the intravenous and the oral routes of administration.

After i.v. and oral administration in humans, Idarubicin is rapidly metabolized to its 13-dihydroderivative (Idarubicinol) and the plasma levels of this metabolite are consistently higher than those of the unchanged drug. Idarubicinol has been shown to be an active metabolite in experimental models, being as potent and as active as the parent compound.

Phase II clinical trials of Idarubicin have indicated that:

By I. V. route

  1. 1.

    Idarubicin is a potent antileukemic agent active in relapsed or refractory ANLL, ALL (adult and pediatric) either as single agent or in combination with Ara-C at doses of 8–12 mg/m2 by i.v. day 1, 2 and 3 or 7–8 mg/m2 i.v. daily × 5 days (adults).

  2. 2.

    There is evidence of lack of cross-resistance with parent drugs and other antileukemic agents. Phase III studies in previously untreated acute leukemias have been initiated.

By oral route

  1. 1.

    Idarubicin has antitumor activity in breast cancer at the doses of 35–45 mg/m2 q 3–4 weeks or 15 mg/m2 daily × 3 days q 3–4 weeks.

  2. 2.

    Idarubicin has activity as a single agent in adult leukemias at the doses of 20–30 mg/m2/day × 3 days.

The safety of administration (no risk of extravasation), the good tolerability and the reduced potential for cardiac toxicity, make oral Idarubicin particular attractive for further clinical development.

Whether Idarubicin proves to be more effective and/or less cardiotoxic in clinical therapy than DNR or DX remains to be seen through prospective randomized studies which have been already initiated both in leukemias and solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arcamone F, Bernardi L, Giardino P, Patelli B, Di Marco A, Casazza AM, Pratesi G, Reggiani P: Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-deme-thoxy-7,9-diepidaunorubicin, and their beta anomers. Cancer Treat Rep, 60:829–834, 1976

    Google Scholar 

  2. Zunino F, Gambetta R, Di Marco A, Luoni G, Zaccaria AA: Effects of the stereochemical configuration on the interaction of some daunomycin derivatves with DNA. Biochem Biophys Res Comm 69 3:744–750, 1976

    Google Scholar 

  3. Arcamone F, Di Marco A, Casazza AM: Chemistry and pharmacology of new antitumor anthracyclines. In: Umezawa H et al. (eds.): Advances in Cancer Chemotherapy, Japan Sci. Soc. Press, Tokyo, Univ, Park Press, Baltimore: 1978, pp 297–312

    Google Scholar 

  4. Supino R, Necco A, Dasdia T, Casazza AM, Di Marco A: Relationship between effects on nucleic acid synthesis in cell cultures and toxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res, 37: 4523–4528, 1977

    Google Scholar 

  5. Casazza AM, Di Marco A, Bonadonna G, Bonfante V, Bertazzoli C, Bellini O, Pratesi G, Sala L, Ballerini L: Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Anthracyclines: Current Status and New Developments. Stanley T. Crooke, Steven D. Reich (Eds.), Academic Press, 1980, pp 403–430

  6. Casazza AM, Pratesi G, Giuliani F, Di Marco A: Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori, 66:549–564, 1980

    Google Scholar 

  7. R. & D. Farmitalia Carlo Erba — Internal Report IMI 30/203: Attività antitumorale di 4-demetossidaunorubicina (IMI 30) su sarcomi e carcinomi sperimentali nel topo (somministrazione e.v., i.p., per os)

  8. Di Marco A, Casazza AM, Pratesi G: Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 61:893–894, 1977

    Google Scholar 

  9. Casazza AM, Bertazzoli C, Pratesi G, Bellini O, Di Marco A: Antileukemic activity and cardiac toxicity of 4-deme-thoxydaunorubicin (4-DMDR) in mice. Proc Am Assoc Cancer Res (Abstract) 20:16, 1979

    Google Scholar 

  10. R. & D. Farmitalia Carlo Erba — Internal Report IMI 30/404-406: Tossicità per somministrazione ripetuta ciclica, per via endovenosa ripetuta per 13 settimane in confronto a adriamicina. Tossicità per somministrazione ripetuta ciclica, per via orale, per 3 mesi nel cane

  11. R.& D. Farmitalia Carlo Erba — Internal Report IMI 30/405: Studio tossicologico nel ratto per somministrazione endovenosa ripetuta per 13 settimane, in confronto a adriamicina

  12. Formelli F, Casazza AM, Di Marco A, Mariani A, Pollini C: Fluorescence assay of tissue distribution of 4-deme-thoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors. Cancer Chemother Pharmacol 3:261–269, 1979

    Google Scholar 

  13. Leyland-Jones B, Kreis W, Baratz R, Lauman L, Kinahan J, Williams L, Wittes RE, Budman D, Young CW: Initial pharmacokinetic evaluation of 4-demethoxydaunorubicin (DMDR) by intravenous and oral administration in patients with solid tumors or acute leukemia. Proc Am Soc Clin Oncol (Abstract) 2:36, 1983

    Google Scholar 

  14. Casazza AM, Barbieri B, Fumagalli A, Geroni MC: Biological activity of 4-demethoxy-13-dihydrodaunorubicin (4-dm-13-OH-DNR). Proc Am Ass Cancer Res (Abstract) 24:251, 1983

    Google Scholar 

  15. Pacciarini MA, Moro E, Tamassia V, Piazza E, Vago G, Belloni A: Pharmacokinetic studies of i.v. and oral 4-demethoxydaunorubicin in man. Proc. 13th Int. Congress of Chemotherapy, Vienna, August 1983, pp 45–50, Part 285

  16. Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW: Phase I and clinical pharmacology studies of intravenous and oral administration of 4-Demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43:6096–6101, 1983

    Google Scholar 

  17. Hoffman N, Miller L, Steinherz L, Hancock C, Miller D, Steinherz P, Tan C: A Phase I study of 4-demethoxydaunorubicin (4-DMDR) in children with advanced malignancy. Proc Am Ass for Cancer Res (Abstract) 24:141, 1983

    Google Scholar 

  18. Steinherz L, Hoffman N, Steinherz P, Miller L, Hancock C, Miller D, Robins J, Tan C: Evaluation of cardiac effects of 4-demethoxydaunorubicin (DMDR) in children. Proc Amer Soc Clin Oncol (Abstract) 2:69, 1983

    Google Scholar 

  19. Bonfante V, Ferrari L, Villani F, Bonadonna G: Phase I study of 4-demethoxydaunorubicin. Invest N Drugs 1:161–168, 1983

    Google Scholar 

  20. Kaplan S, Martini A, Varini M, Togni P, Cavalli F: Phase I trial of 4-demethoxydaunorubicin with single i.v. doses. Eur J Cancer Clin Oncol 18:1303–1306, 1982

    Google Scholar 

  21. Hayat M, Hurteloup P, Parmentier C, Carde P, Pico JO et al.: Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia. Invest N Drugs 2:375–379, 1984

    Google Scholar 

  22. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW: Phase I–II clinical and pharmacology study of 4-demethoxydaunorubicin (Idarubicin) in adult patients with acute leukemia. Cancer Res 45:1408–1412, 1985

    Google Scholar 

  23. Young CW, Arlin ZA, Daghestani AN, Schulman P, Leyland-Jones B: Phase I and Phase II evaluation of 4-demethoxydaunorubicin in acute leukemia. Proc. 13th Int. Congress of Chemotherapy, Vienna, (Abstract) pp 48–50, 1983, Part 215

  24. Lambertenghi-Deliliers G, Pogliani E, Maiolo AT, Pacciarini MA, Polli EE: Therapeutic activity of 4-demethoxydaunorubicin (Idarubicin) in adult acute leukemia. Tumori 69:515–519, 1983

    Google Scholar 

  25. Tamassia V, Goldaniga GC, Moro E, Pacciarini MA, Stegnjaich S, Piazza E: Human pharmacokinetic studies on three new anthracyclines: Epirubicin, Idarubicin, Esorubicin. Fourth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, Belgium, Dec. 1983. Proceedings (Abstract) 1983

  26. Lambertenghi-Deliliers G, Maiolo AT, Annaloro C, Pogliani E, Baldini L, Polli EE: Complete Remission in prolymphocytic leukemia with 4-demethoxodaunorubicin and arabinosyl-cytosine. Cancer 54:199–201, 1984

    Google Scholar 

  27. Carella AM, Santini G, Nati S, Martinengo M, Cerri R, Congiu M, Barra S, Saluscev P, Marmont AM: Phase II trial of Idarubicin (IMI 30) in 16 refractory or relapsed acute leukemia (AL) patients. 4th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, Belgium, Proceedings (Abstract) 1983

  28. Berman E, Arlin Z, Daghestani T, Gee S, Kempin S, Mertelsmann R et al.: Phase I–II study of Idarubicin and Cytarabine (Ara-C) in acute leukemia. Proc Am Assoc Cancer Res (Abstract), Toronto, p. 187, 1984

  29. Mandelli F, Testi AM, Aloe Spiriti MA, Giona F, Meloni G, Moleti ML, Amadori S: Evaluation of polichemotherapeutic schedule including 4-Demethoxydaunorubicin in relapsed acute limphocytic leukemia. Haematologica (in press) 1985

  30. Eridani S, Slater NGP, Singh AK, Pearson TC: Intravenous and oral demethoxydaunorubicin (NSC 256–439) in the treatment of acute leukemia and lymphoma: a pilot study. Blut 50:369–372, 1985

    Google Scholar 

  31. Lambertenghi-Deliliers G, Pogliani E, Maiolo AT, Pacciarini MA, Polli EE: Therapeutic activity of i.v. and oral Idarubicin (IMI 30) in acute leukemia. 4th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, Belgium (Abstract) 1983

  32. Carella AM, Santini G, Martinengo M, Giordano D, Nati S, Congiu A, Cerri R, Risso M, Damasio E, Rossi E, Vimercati R, Pacciarini MA, Marmont AM: 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias: A pilot study. Cancer. 55:1452–1454, 1985

    Google Scholar 

  33. Lambertenghi-Deliliers G, Pogliani E, Annaloro C, Pacciarini MA, Polli EE: Oral Idarubicin in adult acute leukemia: a preliminary experience. Haematologica (submitted), 1985

  34. Joss RA, Obrecht JP, Alberto P et al.: Phase II trial of 4-Demethoxydaunorubicin (IMI 30) in patients with nonsmall cell lung cancer (NSCLC). Proc. 13th Int. Congress of Chemotherapy, Vienna, August 1983, in Symposium New Anthracyclines in the Chemotherapy of Solid Tumors and Haematologic Malignancies SY 88, pp 53–55, 1983

  35. Stanton G, Casper ES, Friedman B: Phase II trial of 4-Demethoxydaunorubicin in patients with advanced malignant melanoma. Cancer Treat Rep (in press) 1984

  36. Harper HD, Kemeny NE, Ahmed T, Cheng E, et al: Phase II trial of 4-Demethoxydaunorubicin in advanced colorectal carcinoma. Cancer Treat Rep, 68, 1984

  37. Einzig A, Kelsen D, Cheng E, Sordillo P, et al: Phase II study of 4-Demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract. Cancer Treat. Rep (in press) 1984

  38. Raymond V, Magill GB, Welt S, Kruger G, et al: 4-Demethoxydaunorubicin (DMDR) in advanced soft tissue sarcomas (STS). A phase II study. Proc Am Soc Clin Oncol 235, 1983

  39. Coonley CJ, Warrel RP Jr, Straus DJ, Young CW: Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma. Cancer Treat Rep 67:949–950, 1983

    Google Scholar 

  40. Mittelman A, Magill G, Raymond V, Cheng E et al: Phase II trial of 4-Demethoxydaunorubicin (DMDR) in patients (PTS) with pancreatic carcinoma (Ca). Proc Am Soc Clin Oncol (Abstract) 140, 1984

  41. Wissel P, Magill G, Raymond V, Welt S et al: 4-Demethoxydaunorubicin (DMDR) in advanced soft tissue sarcomas: an update with emphasis on patients (PTS) without prior doxorubicin (DX). Proc Am Soc Clin Oncol (Abstract) 259, 1984

  42. Kampel LJ, Dosik M, Yagoda A, Young CW: A Phase II trial of oral 4-Demethoxydaunorubicin (DMDR) in previously untreated patients with advanced colorectal carcinoma. Proc Amer Soc Clin Oncol (Abstract) 140, 1984

  43. Martoni A, Tomasi L, Pacciarini MA, Pannuti F: Preliminary results of 4-Demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. Comm. at the 6th Int. Symposium on Future Trends in Chemotherapy, Tirrenia (Italy), May 28–30, (Abstract) 118, 1984

  44. Bandini G, Comotti B, Scapoli G, Leoni F, Di Prisco U, Rangoni L, Battista R, Tura S: Effect of 4-Demethoxydaunorubicin (4-DMDR) in chronic myeloid leukemia in blastic transformation and relapsed acute leukemias. Haematologica, 70:155–159, 1985

    Google Scholar 

  45. Battista R, D'Emilio A, Vespignani M, Pacciarini MA, Dini E: Preliminary observations on intravenous Idarubicin (4-Demethoxydaunorubicin) in the chronic and accelerated phase of chronic myelogenous leukemia. Tumori (Submitted), 1985

  46. Madon E, Carli M, Ceci A, De Bernardi B, Di Pietro N, Paolucci G, Turra R: Phase II study of Idarubicin (4-Demethoxydaunorubicin) in pediatric acute leukemias and solid tumors. Comm. at 3rd European Conference on Clinical Oncology, Stockholm, June 1985

  47. Carella AM, Santini G, Giordano D, Frassoni F, Martinengo M, Congiu A, Nati S, Risso M, Cerri R, Marmont A: Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non lymphoblastic leukaemia. Leukemia Research 9:631, 1985

    Google Scholar 

  48. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47:207–214, 1981

    CAS  PubMed  Google Scholar 

  49. Martoni A, Pacciarini MA, Pannuti F: The new anthracycline 4-Demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma: a pilot study. Drugs under Experimental and Clinical Research, XI:127–131, 1985

    Google Scholar 

  50. Lopez M, Di Lauro L, Papaldo P, Lazzaro B et al: Phase II trial with oral Idarubicin in advanced breast cancer. Invest N Drugs (In press), 1984

  51. Pronzato P, Ardizzoni A, Grimaldi A, Repetto L, Lionetto R, et al: Impiego della 4-Demetossidaunorubicina (4-dmDNR) orale nel trattamento dei tumori solidi. Comm: 3° Corso di Aggiornamento in Farmacologia Clinica. Antitumor Antibiotics, Padua, October 4–6, 1984

  52. Lopez M, Lazzaro B, Di Lauro L, Papaldo P et al: Phase II study of oral 4-Demethoxydaunorubicin in advanced malignant melanoma. Comm. at 14th Int. Congress of Chemotherapy, Kyoto, June 1985

  53. Kaplan S, Sessa C, Willems Y, Pacciarini MA et al: Phase I trial of 4-demethoxydaunorubicin (Idarubicin) with single oral doses. Invest N Drugs, 2:281–286, 1984

    Google Scholar 

  54. Bonfante V, Rossi A, Brambilla C, Ferrari L, Villani F, Comazzi R, Crippa F, Monfardini S, Bonadonna G: Comparative activity and toxicity of Adriamycin (ADM) and new anthracycline analogs in advanced breast cancer. Proc Am Assoc Cancer Res (Abstract) 26:165, 1985

    Google Scholar 

  55. Bastholt L, Ejlertsen B, Dalmark B: A phase II trial of oral 4-Demethoxydaunorubicin (DMDR) in patients with measurable advanced carcinoma of the breast. Proc Am Assoc Cancer Res (Abstract), 26:164, 1985

    Google Scholar 

  56. Pannuti F, Martoni A, Camaggi CM, Strocchi E, Pacciarini MA: 4-Demethoxydaunorubicin in advanced breast cancer and melanoma: clinical aspects and pharmacokinetics. Comm. at 14th International Congress of Chemotherapy, Kyoto, June 1985

  57. Camaggi CM, Strocchi E, Comparsi R, Martoni A, et al: Low-dose oral administration of 4-Demethoxydaunorubicin in advanced cancer patients. A pharmacokinetic study. Comm. 3rd Europ. Conference on Clin. Oncol., Stockholm, June 16–20, 1985

  58. Tan C, Bacha D, Hancock C: New anthracyclines in childhood cancer. Comm. at 14th Int. Congress of Chemotherapy, Kyoto, June 1985

  59. Tan C, Miller L, Hancock C, Mondora A, Steinherz P, Miller D: Anthracycline in childhood cancer. Comm. XIVth Meeting of the International Society of Pediatric Oncology, Bern 21–25 Sept, 1982

  60. Ohashi K, Gillies HC, Rogers HJ, Harper PG: Pharmacokinetics of Idarubicin (IMI 30). An orally administered anthracycline. Comm. at 14th Int. Congress of Chemotherapy, Kyoto, June 1985

  61. Wertheim MS, Kris TG, Gralla RJ, O'Connell JP, Fiore JJ, et al: Phase II studies of three new anthracyclines in Non-Small Cell Lung Cancer. Proc Am Soc Clin Oncol (Abstract) 4:190, 1985

    Google Scholar 

  62. Cheng E, Chun H, Schiff C, Kemeny N, Sordillo P, Young CW: Phase II trial of oral 4-Demethoxydaunorubicin (DMDR) in patients with primary liver carcinoma. Proc Am Soc Clin Oncol (Abstract), 4:88, 1985

    Google Scholar 

  63. Ten Bokkel Huinink WW, Cavalli F, Renard J, Van Glabekke M, Clarysse A: EORTC Early Clinical Trials Group: Esorubicin versus Idarubicin with a cross-over to doxorubicin in breast cancer; a randomized Phase II trial. Comm. st the 10th Annual Meeting of the ESMO, 62, 1984 (Springer International Ed.)

  64. Stuart NS, Cullen MH, Blackledge GRP, Priestman TJ, Spooner D: Phase II study of oral 4-Demethoxydaunorubicin in advanced breast cancer. Comm. 3rd European Conference on Clinical Oncology (ECCO), Stockholm, June 16–20, 1985

Download references

Author information

Authors and Affiliations

  1. R. & D. Farmitalia Carlo Erba S.p.A., Milan, Italy

    F. Ganzina, M. A. Pacciarini & N. Di Pietro

Authors
  1. F. Ganzina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Pacciarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Di Pietro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganzina, F., Pacciarini, M.A. & Di Pietro, N. Idarubicin (4-demethoxydaunorubicin). Invest New Drugs 4, 85–105 (1986). https://doi.org/10.1007/BF00172021

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172021

Key words

Search

Navigation